Ruth M O'Regan (Ruth O'Regan)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 14

Top Topics

Positive Breast Cancer

Clinical Practice

Mesenchymal Stem Cells

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Future oncology (London, England)

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Xiaojia Wang, Ruth M O'Regan
Breast cancer therapy in China: Introducing the Special Collection. Cancer (2024)
Xiaojia Wang, Ruth M O'Regan
Breast cancer therapy in China: Introducing the Special Collection. Cancer 130 (S8) (2024)
Xiaojia Wang, Ruth M O'Regan
Breast cancer therapy in China: Introducing the Special Collection. Cancer 130 (S8) (2024)
Kevin M Kalinsky, Melissa K Accordino, Codruta Chiuzan, Prabhjot S Mundi, Elizabeth Sakach, Claire Sathe, Heejoon Ahn, Meghna S Trivedi, Yelena Novik, Amy Tiersten, George Raptis, Lea N Baer, Sun Y Oh, Amelia B Zelnak, Kari B Wisinski, Eleni Andreopoulou, William J Gradishar, Erica M Stringer-Reasor, Sonya A Reid, Anne O'Dea, Ruth M O'Regan, Katherine D Crew, Dawn L Hershman
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
William J Gradishar, Ruth M O'Regan, Mothaffar F Rimawi, Jeffrey L Nordstrom, Minori K Rosales, Hope S Rugo
Margetuximab in HER2-positive metastatic breast cancer. Future oncology (London, England) (2023)
Arya Mariam Roy, Vasanthan Muthusamy Kumarasamy, Ajay Dhakal, Ruth M O'Regan, Shipra Gandhi
A review of treatment options in HER2-low breast cancer and proposed treatment sequencing algorithm. Cancer (2023)
David Hicks, Ruth M O'Regan
Improving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer With CDK Inhibition. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (11) (2022)
Ticiana A Leal, Marina N Sharifi, Nancy Chan, Robert Wesolowski, Anita A Turk, Justine Y Bruce, Ruth M O'Regan, Jens Eickhoff, Lisa M Barroilhet, Jyoti Malhotra, Janice Mehnert, Eugenia Girda, Elizabeth Wiley, Natalie Schmitz, Shannon Andrews, Glenn Liu, Kari B Wisinski
A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782). Cancer medicine 11 (21) (2022)
Jane Lowe Meisel, Amy Harrington, Natalie Whaley, Wendy Vitek, Ruth M O'Regan
When the personal becomes political: The impact of the Dobbs decision on women with cancer. Cancer (2022)
Christina M Scribano, Jun Wan, Karla Esbona, John B Tucker, Amber Lasek, Amber S Zhou, Lauren M Zasadil, Ryan Molini, Jonathan Fitzgerald, Angela M Lager, Jennifer J Laffin, Kayla Correia-Staudt, Kari B Wisinski, Amye J Tevaarwerk, Ruth M O'Regan, Stephanie M McGregor, Amy M Fowler, Richard J Chappell, Tim S Bugni, Mark E Burkard, Beth A Weaver
Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel. Science translational medicine 13 (610) (2021)
Ajay Dhakal, Carla Falkson, Ruth M O'Regan
Adjuvant cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive breast cancer: One Monarch to rule them all? Cancer 127 (18) (2021)
Marina N Sharifi, Apoorva Anandan, Patrick Grogan, Ruth M O'Regan
Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies. Cancer 126 (15) (2020)
Fadlo R Khuri, Ruth M O'Regan
Progress in breast cancer research amid the COVID-19 gloom. Cancer (2020)
Jane Lowe Meisel, Ruth M O'Regan
Race, breast cancer, and prognosis: Where biology is queen? Cancer 125 (18) (2019)